Literature DB >> 27820607

Promotion of Drugs for Off-label Uses: The US Food and Drug Administration at a Crossroads.

Jeanie Kim1, Amy Kapczynski1.   

Abstract

Mesh:

Year:  2017        PMID: 27820607     DOI: 10.1001/jamainternmed.2016.7151

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN: 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  4 in total

1.  Direct-to-Consumer Broadcast Advertisements for Pharmaceuticals: Off-Label Promotion and Adherence to FDA Guidelines.

Authors:  Kristina Klara; Jeanie Kim; Joseph S Ross
Journal:  J Gen Intern Med       Date:  2018-02-26       Impact factor: 5.128

2.  Accuracy of health-related information regarding COVID-19 on Twitter during a global pandemic.

Authors:  Sarah B Swetland; Ava N Rothrock; Halle Andris; Bennett Davis; Linh Nguyen; Phil Davis; Steven G Rothrock
Journal:  World Med Health Policy       Date:  2021-07-29

3.  Assessing the potential clinical impact of reciprocal drug approval legislation on access to novel therapeutics in the USA: a cohort study.

Authors:  Matthieu Larochelle; Nicholas S Downing; Joseph S Ross; Frank S David
Journal:  BMJ Open       Date:  2017-02-08       Impact factor: 2.692

4.  Pharmaceutical Drugs of Uncertain Value, Lifecycle Regulation at the US Food and Drug Administration, and Institutional Incumbency.

Authors:  Matthew Herder
Journal:  Milbank Q       Date:  2019-08-12       Impact factor: 4.911

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.